Further supporting evidence for the therapeutic BDNF/TrkB immunomodulation mechanism is observed in models of post-stroke injury [151], depression [152], multiple sclerosis [153], and TBI [154] through anti-inflammatory effects that would protect from the potential damaging consequences of neuroinflammation or signaling disruptions by its mediators [155]. This evidence concerns the gene NTRK2 and major depressive disorder.